Sign In
Buy KRON
$0.88
+0 (+0%)
At Close: Sep 19, 2025
Kronos Bio Completes Sale to Concentra Biosciences
01:19pm, Friday, 20'th Jun 2025
Kronos Bio completed its sale to Concentra Biosciences for 57 cents a share in cash plus contingent value rights related to cost savings and potential proceeds from disposition of drug candidates.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON
05:30pm, Thursday, 01'st May 2025
NEW YORK , May 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
09:54am, Thursday, 01'st May 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to l
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
09:34am, Thursday, 01'st May 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kronos Bio, Inc. (NASDAQ: KRON) to Concentra Biosciences, LLC for $0.57 in cash per share
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
08:30am, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and o
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Tuesday, 18'th Mar 2025
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial res
Kronos Bio Announces CEO Transition and Reduction in Force
07:30am, Wednesday, 27'th Nov 2024
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D.
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
04:02pm, Thursday, 14'th Nov 2024
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo model
Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
06:36pm, Wednesday, 13'th Nov 2024
Piper Sandler analyst Edward Tenthoff downgraded Kronos Bio to Neutral from Overweight with a price target of $1, down from $6.
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
06:31pm, Wednesday, 13'th Nov 2024
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.54 per share a year ago.
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
08:55am, Wednesday, 23'rd Oct 2024
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
08:55am, Wednesday, 09'th Oct 2024
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease
08:55am, Monday, 07'th Oct 2024
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor r
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
08:55am, Wednesday, 25'th Sep 2024
– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammato
